Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 6/20 | 0.49 |
| ▸ | HTR1D | P28221 | 5/20 | 0.49 |
| ▸ | HTR1B | P28222 | 4/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | PRKCB | P05771 | 2/20 | 0.45 |
| ▸ | PRKCA | P17252 | 2/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | MPO | P05164 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29673213 | 1.00 | HTR1A (0.49) | HTR1AHTR1DHTR1BATMPRKCB | |
| SCHEMBL15730167 | 0.85 | ATM (0.47) | HTR1AHTR1DHTR1BATMPRKCB | |
| SCHEMBL10299400 | 0.83 | HTR1D (0.58) | HTR1AHTR1DHTR1BATMGABRA1 | |
| SCHEMBL19846980 | 0.81 | ATM (0.47) | HTR1AHTR1DHTR1BATMHTR2A | |
| SCHEMBL12244212 | 0.81 | ATM (0.47) | HTR1AHTR1DHTR1BATMGABRA1 | |
| SCHEMBL8297234 | 0.79 | HTR1D (0.67) | HTR1AHTR1DHTR1BHTR2AHTR2B | |
| SCHEMBL7214908 | 0.78 | HTR1A (0.45) | HTR1AHTR1DHTR1BPRKCBPRKCA | |
| SCHEMBL29853703 | 0.78 | HTR1A (0.45) | HTR1AHTR1DHTR1BPRKCBPRKCA | |
| SCHEMBL18853913 | 0.77 | HTR2A (0.49) | HTR1AHTR1DHTR1BHTR2AHTR2B | |
| Hydrochloric Acid SCHEMBL29792486 | 0.76 | HTR1A (0.44) | HTR1AHTR1DHTR1BPRKCBPRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115052860-B | Collagen 1 translation inhibitors and methods of use thereof | 艾尼莫生物科技公司 | 2024-06-21 | — | — | CN | disclosed |
| US-20230116201-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2023-04-13 | — | — | US | disclosed |
| EP-4097084-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | Anima Biotech Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| CN-115052860-A | Collagen 1 translation inhibitors and methods of use thereof | 艾尼莫生物科技公司 | 2022-09-13 | — | — | CN | disclosed |
| WO-2021154902-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| WO-2021154902-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| WO-2021055621-A1 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2021-03-25 | — | — | WO | disclosed |
| US-20180037917-A1 | PROTECTING GROUP CHEMISTRY FOR CLEAN, REDUCTANT-FREE DYEING | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-02-08 | — | — | US | disclosed |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2017-05-18 | — | — | US | disclosed |
| US-9540343-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| WO-2013026914-A1 | SERINE/THREONINE PAK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-28 | — | — | WO | disclosed |
| US-20120252853-A1 | Positive allosteric modulators of nicotinic acetylcholine receptor | H. LUNDBECK A/S (DK) | 2012-10-04 | — | — | US | disclosed |
| US-20120252853-A1 | Positive allosteric modulators of nicotinic acetylcholine receptor | H. LUNDBECK A/S (DK) | 2012-10-04 | — | — | US | disclosed |
| US-20120252853-A1 | Positive allosteric modulators of nicotinic acetylcholine receptor | H. LUNDBECK A/S (DK) | 2012-10-04 | — | — | US | disclosed |
| WO-2012131031-A1 | NEW POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTOR | H. LUNDBECK A/S (DK) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012131031-A1 | NEW POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTOR | H. LUNDBECK A/S (DK) | 2012-10-04 | — | — | WO | disclosed |
| EP-0997474-B1 | Antithrombotic agents | PFIZER (US) | 2003-10-29 | — | — | EP | disclosed |
| US-6417203-B1 | HETEROCYCLIC AMIDES | PFIZER INC. | 2002-07-09 | — | — | US | disclosed |
| US-6180627-B1 | INDOLE, INDAZOLE, BENZOTRIAZOLE AND BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2001-01-30 | — | — | US | disclosed |
| EP-0997474-A1 | Antithrombotic agents | PFIZER INC. (US) | 2000-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252853-A1 | Positive allosteric modulators of nicotinic acetylcholine receptor | CHRNG, CHRNA7, CHRNA2 | HTR1A 333/4885HTR1D 883/4885HTR1B 399/4885 |
| US-20230116201-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | COL1A1, COL2A1, COL14A1 | HTR1A 2470/4885HTR1D 2349/4885HTR1B 2882/4885 |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | HTR1A 4710/4885HTR1D 4753/4885HTR1B 4456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.